Fullerene-based mimics of enhanced acetylcholine detection for the diagnosis of Alzheimer’s disease

Soylemez, Saniye; Dolgun, Volkan; Özçubukçu, Salih

doi:10.1016/j.microc.2023.109099

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, amyloid-beta (Aβ), phosphorylated tau (p-tau), and total-tau (t-tau) biomarkers are broadly approved as fingerprints of AD [4][5][6]. In contrast, few studies are working on acetylcholine [7,8] and α-synuclein [9]. Previous longitudinal and crosssectional research has indicated that prior to showing AD symptoms, the levels of Aβ 1-42 , p-tau, and t-tau start to change after roughly 10-15 years [10,11].…”

Section: Introductionmentioning

confidence: 99%

Alzheimer’s Disease Biomarker Detection Using Field Effect Transistor-Based Biosensor

Le,

Choi,

Cho

2023

Biosensors

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is closely related to neurodegeneration, leading to dementia and cognitive impairment, especially in people aged > 65 years old. The detection of biomarkers plays a pivotal role in the diagnosis and treatment of AD, particularly at the onset stage. Field-effect transistor (FET)-based sensors are emerging devices that have drawn considerable attention due to their crucial ability to recognize various biomarkers at ultra-low concentrations. Thus, FET is broadly manipulated for AD biomarker detection. In this review, an overview of typical FET features and their operational mechanisms is described in detail. In addition, a summary of AD biomarker detection and the applicability of FET biosensors in this research field are outlined and discussed. Furthermore, the trends and future prospects of FET devices in AD diagnostic applications are also discussed.

show abstract